Safety and Targeting of Anti-hk2 Antibody in mCRPC

Inclusion Criteria:

Subjects with mCRPC will be eligible if they meet the following criteria:
Eastern Cooperative Oncology Group (ECOG) ≤ 1
Histologically or cytologically confirmed adenocarcinoma of the prostate
Castrate levels of testosterone (<50 ng/dL [1.74 nmol/L])
Metastatic disease documented by imaging
Documented progressive mCRPC with androgen involvement as defined by - Prostate Cancer Working Group 3
Acceptable laboratory parameters
At least 28 days since administration of any therapeutic radioactive isotope
Able to tolerate the conditions required to perform imaging studies (e.g., lying flat for at least 1 hour).

Exclusion Criteria:

Known hypersensitivity to proteins, or other allergic diathesis that, in the opinion of the investigator, makes an immune response to humanized antibody likely
Radiotherapy or immunotherapy within 30 days, or single fraction of palliative radiotherapy within 14 days of administration of study agent
Any condition that, in the opinion of the Investigator, would impair the subject's ability to comply with study procedures and required study visits
Active, symptomatic, or untreated brain metastases.